Cytarabine and Jaundice cholestatic - a phase IV clinical study of FDA data

Summary:

Jaundice cholestatic is reported as a side effect among people who take Cytarabine (cytarabine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Methotrexate, and have Infection.

The phase IV clinical study analyzes which people have Jaundice cholestatic when taking Cytarabine. It is created by eHealthMe based on reports of 65,319 people who have side effects when taking Cytarabine from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Jaundice cholestatic?

Jaundice cholestatic is found to be associated with 536 drugs and 983 conditions by eHealthMe. Check the latest studies of Jaundice cholestatic.

On Jul, 04, 2026

65,319 people reported to have side effects when taking Cytarabine.
Among them, 40 people (0.06%) have Jaundice cholestatic.

Could Cytarabine cause Jaundice cholestatic?

Among these 40 people:

How long have people been on Cytarabine when they have Jaundice cholestatic? *

What is the gender of people who have Jaundice cholestatic when taking Cytarabine? *

female: 7.89 %
male: 92.11 %

What is the age of people who have Jaundice cholestatic when taking Cytarabine? *

What are other drugs people take besides Cytarabine? *

What are other side effects people have besides Jaundice cholestatic? *

Hepatotoxicity (chemical-driven liver damage): 5 people, 12.50%
Hepatic Failure (liver failure): 5 people, 12.50%
Hepatocellular Injury (liver injury): 5 people, 12.50%
Hyperbilirubinaemia (excess of bilirubin in the blood): 5 people, 12.50%
Hyperammonaemia: 4 people, 10.00%
Hypotension (abnormally low blood pressure): 4 people, 10.00%
Drug Toxicity: 4 people, 10.00%
Generalised Oedema (swelling all over the body): 3 people, 7.50%
Hepatitis (inflammation of the liver): 3 people, 7.50%
Heart Rate Decreased: 3 people, 7.50%

What are the existing conditions these people have? *

Infection: 13 people, 32.50%
Burkitt Lymphoma (cancer of the lymphatic system): 9 people, 22.50%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 9 people, 22.50%
Diabetes: 8 people, 20.00%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 6 people, 15.00%
B Precursor Type Acute Leukaemia (lymphoid cancer): 3 people, 7.50%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 5.00%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 5.00%
Bone Marrow Conditioning Regimen: 2 people, 5.00%
Type 2 Diabetes: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and have Jaundice cholestatic?

- Check whether Jaundice cholestatic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cytarabine:

Cytarabine (65,358 reports)

Browse all side effects of Cytarabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Jaundice cholestatic:

Jaundice cholestatic (536 drugs)

Browse all the conditions that are associated with Jaundice cholestatic:

Jaundice cholestatic (983 conditions)

Related publications that referenced our studies

Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M, "Cephalexin Induced Cholestatic Jaundice", Case reports in gastrointestinal medicine, 2014 Aug .
Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M, "Cephalexin Induced Cholestatic Jaundice", Case reports in gastrointestinal medicine, 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on cytarabine (the active ingredients of Cytarabine) and Cytarabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.